A Phase 1 Clinical Study to Evaluate the Absorption, Metabolism and Excretion of [14C]MK-8189 in Healthy Adults
Latest Information Update: 09 Oct 2024
At a glance
- Drugs MK 8189 (Primary)
- Indications Alzheimer's disease; Bipolar disorders; Schizophrenia
- Focus Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 09 Oct 2024 New trial record